You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
A simple assay system for rapid detection of circulating tumor cells
SBC: TELOVISION, LLC Topic: NCIDESCRIPTION provided by applicant Metastasis or dissemination of primary tumor cells is the major cause of mortality in cancer patients Circulating tumor cells CTCs in the bloodstream are key players in the establishment of metastatic tumors Recent studies demonstrated that the number of CTCs present in patient blood directly correlate with cancer progression recurrence and survival rate ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Cell Therapy for the Treatment of Acute Respiratory Distress Syndrome
SBC: ATHERSYS, INC. Topic: NIAAADESCRIPTION (provided by applicant): This is a resubmission of a Phase I-Phase II Fast-Track application for the clinical use of MultiStem in patients with acute respiratory distress syndrome (ARDS). ARDS is defined as acute onset hypoxemia, bilateral radiographic pulmonary infiltrates and lack of atrial pressure hypertension. A novel and exiting possibility is the use of cells as part of the ther ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Combinatorial RXR-based therapeutics for Alzheimer's disease
SBC: REXCEPTOR, INC. Topic: NIADESCRIPTION (provided by applicant): The principle objective of this application is the development of safer and more effective combinatorial therapy for AD. ReXceptor, Inc. is developing new therapeutics for the treatment of AD based on stimulating the physiological clearance mechanisms of soluble forms of A from the brain. Bexarotene is an agonist of the ligand-activated transcription factor, r ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Computer-based Prescription Opioid Abuse Prevention for Adolescents
SBC: HEALTHSIM, INC. Topic: R42DESCRIPTION provided by applicant Recreational use of prescription opioids among adolescents is a significant and growing public health concern and has been referred to as an emerging epidemic in the U S Although a number of science based interactive drug abuse prevention programs exist focused on preventing use of non prescription drugs among youth to our knowledge no science based inter ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Corneal Endothelial Stem Cells for Treatment of Corneal Endothelial Dystrophies
SBC: RASHMIVU LLC Topic: NDESCRIPTION provided by applicant Corneal clouding caused by failure of the corneal endothelial deturgesence mechanism affects over million people in the US and well over million people worldwide It is the most common corneal disease and is historically a common cause of blindness Surgical treatment by corneal grafting has been successful when available but is limited by the availabili ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development and in vitro validation of therapy for mucopolysaccharidosis III
SBC: Phoenix Nest Inc. Topic: 105DESCRIPTION provided by applicant Sanfilippo disease mucopolysaccharidosis type III MPS III is a devastating neurodegenerative lysosomal storage disorder of childhood for which there is no cure or effective treatment available The fundamental cause of MPS III is an inherited mutation in one of the enzymes required to catabolize heparan sulfate HS a glycosaminoglycan which plays importa ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of an Antigen Capture Assay for Babesia microti
SBC: BIOPEPTIDES CORP Topic: NIAIDDESCRIPTION provided by applicant Babesia microti the primary etiologic agent of human babesiosis is a tick borne eukaryotic apicomplexan pathogen that is an increasing threat to the US public health Although B microti is primarily a tick borne pathogen it can be transmitted by transfusion of infected blood Despite the well recognized threat there is no FDA licensed test to screen donor ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of a new approach to screening for language impairments
SBC: PANTHER TECHNOLOGY Topic: NIDCDDESCRIPTIONprovided by applicantThis Small Business Technology and TransferSTTRFast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language ImpairmentSLIinto an innovativeeasy touse app based screener with high potential for private sector commercializationSLI is a form of language impairment with no known causewith a strong research baseBecause ...
STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health -
Development of Compounds for the Prevention and Treatment of Rhabdomyolysis
SBC: Virtual Drug Development Inc. Topic: NIDDK? DESCRIPTION (provided by applicant): The goal of this Phase I STTR project is to establish the feasibility of developing a small-molecule therapeutic agent designed to prevent rhabdomyolysis-induced renal failure. Rhabdomyolysis accounts for 7% to 10% of cases of renal failure in the US. Rhabdomyolysis results from muscle injury that leads to the release of myoglobin, which is then deposited ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
Enhancing mtDNA Repair During Stroke Reperfusion to Reduce Brain Damage
SBC: EXSCIEN CORPORATION Topic: NINDSDESCRIPTION (provided by applicant): Attempts to develop drug treatments for acute stroke have not fulfilled expectations. Perhaps best illustrating this unsatisfactory situation is the hisory of therapeutic strategies directed at the inhibition of reactive oxygen species (ROS). While decades of laboratory and clinical studies make it clear that ROS are pathogenically important across the entire s ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health